Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MIRA Mira Pharma

Trading 06-24 14:11:51 EDT

0.9311

-0.0229

-2.40%

High0.9697	Low0.9309	Vol37.79K
Open0.9665	D1 Closing0.9540	Amplitude4.07%
Mkt Cap38.99M	Tradable Cap32.54M	Total Shares41.88M
T/O35.95K	T/O Rate0.11%	Tradable Shares34.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MIRA","market":"US","secType":"STK","nameCN":"Mira Pharma","latestPrice":0.9311,"timestamp":1782324537471,"preClose":0.954,"halted":0,"volume":37789,"delay":0,"changeRate":-0.024004192872117316,"floatShares":34944200,"shares":41876087,"eps":-1.4419,"marketStatus":"Trading","change":-0.0229,"latestTime":"06-24 14:11:51 EDT","open":0.9665,"high":0.9697,"low":0.9309,"amount":35953.678963599996,"amplitude":0.040671,"askPrice":0.95,"askSize":602,"bidPrice":0.9309,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-1.4419,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1782331200000},"marketStatusCode":2,"adr":0,"listingDate":1691035200000,"exchange":"NASDAQ","adjPreClose":0.954,"preHourTrading":{"tag":"盘前","latestPrice":0.94,"preClose":0.954,"latestTime":"09:00 EDT","volume":4286,"amount":4029.10388902,"timestamp":1782306043834,"change":-0.014,"changeRate":-0.014675,"amplitude":0.041929},"postHourTrading":{"tag":"盘后","latestPrice":0.93,"preClose":0.954,"latestTime":"19:27 EDT","volume":2941,"amount":2774.3612,"timestamp":1782257273606,"change":-0.024,"changeRate":-0.025157,"amplitude":0.025157},"volumeRatio":0.598879},"requestUrl":"/m/hq/s/MIRA/wiki","defaultTab":"wiki","newsList":[{"id":"2644745903","title":"Mira Pharmaceuticals - Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2644745903","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644745903?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:04","pubTimestamp":1781697871,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nFWN42O0RI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644981745","title":"Mira Pharmaceuticals submits FDA Phase 2a trial protocol for Ketamir-2 in chemotherapy-induced neuropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2644981745","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644981745?lang=en_us&edition=fundamental","pubTime":"2026-06-17 20:02","pubTimestamp":1781697737,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals submitted an FDA Phase 2a trial protocol for Ketamir-2 to treat chemotherapy-induced peripheral neuropathy.Planned randomized, double-blind, placebo-controlled crossover study tests 300 mg, 600 mg doses in patients with persistent moderate-to-severe pain.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL6nD8FX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642049098","title":"Mira Pharmaceuticals CFO Andriy Mushak files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2642049098","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642049098?lang=en_us&edition=fundamental","pubTime":"2026-06-10 05:01","pubTimestamp":1781038870,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals filed a Form 3 naming Andriy Mushak as chief financial officer in an initial statement of beneficial ownership dated June 2, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDLbdbNSP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642437154","title":"MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2642437154","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642437154?lang=en_us&edition=fundamental","pubTime":"2026-06-09 06:44","pubTimestamp":1780958645,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has issued an announcement. On June 6, 2026, MIRA Pharmaceuticals, Inc. implemented a leadership change in i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-appoints-new-fractional-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-appoints-new-fractional-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642643477","title":"BRIEF-Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2642643477","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642643477?lang=en_us&edition=fundamental","pubTime":"2026-06-09 05:17","pubTimestamp":1780953426,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC FilingJune 8  - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS - ALAN WEICHSELBAUM TO STEP DOWN AS CFO EFFECTIVE JUNE 6, 2026 - SEC FILINGMIRA PHARMACEUTICALS - APPOINTS ANDRIY MUSHAK AS FRACTIONAL CFO EFFECTIVE JUNE 6, 2026 - SEC FILINGSource text: [ID:n0001493152-26-027751]Further company coverage: MIRA.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nFWN42G13I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642843417","title":"Mira Pharmaceuticals names Andriy Mushak fractional CFO, replacing Alan Weichselbaum","url":"https://stock-news.laohu8.com/highlight/detail?id=2642843417","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642843417?lang=en_us&edition=fundamental","pubTime":"2026-06-09 05:01","pubTimestamp":1780952485,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals named Andriy Mushak fractional chief financial officer effective June 6, 2026.Outgoing CFO Alan Weichselbaum leaves the role June 6, 2026; departure not tied to any disagreements over operations, policies, or practices.Mushak is a CPA with more than 20 years of SEC reporting, accounting compliance, and audit experience.He is a partner at LMAM Consulting Group; previously spent over a decade at Baker Tilly US in audit, most recently as a senior manager.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission ,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDL7m0fXN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640015157","title":"MIRA Pharmaceuticals Secures Unified Global Rights to Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2640015157","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640015157?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:35","pubTimestamp":1780576512,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has shared an announcement. On June 3, 2026, MIRA Pharmaceuticals, Inc. entered into an amended and restated...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-secures-unified-global-rights-to-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-secures-unified-global-rights-to-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640015227","title":"Mira Pharmaceuticals Inc: Controls Global Development Rights Across Entire Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2640015227","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640015227?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:03","pubTimestamp":1780574582,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nFWN42C0M8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640521021","title":"Mira Pharmaceuticals secures worldwide exclusive rights to MIRA-55 and SKNY-1 in amended license deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2640521021","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640521021?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:00","pubTimestamp":1780574430,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals executed an amended exclusive license with MIRALOGX, securing worldwide exclusive rights to MIRA-55 and SKNY-1.Deal grants global development, commercialization, sublicensing, IP enforcement rights for both assets, tightening control of the company’s pipeline.MIRA-55 is an oral investigational candidate for chronic inflammatory pain; SKNY-1 targets obesity and addiction-related disorders.Amendment leaves previously disclosed core economic terms of existing license arrangements largely unchanged.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL793X6h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Mira Pharmaceuticals secures worldwide exclusive rights to MIRA-55 and SKNY-1 in amended license deal","news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638688567","title":"MIRA Expands Global Ketamir-2 License for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2638688567","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638688567?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:37","pubTimestamp":1779885424,"startTime":"0","endTime":"0","summary":"An announcement from MIRA Pharmaceuticals, Inc. ( ($MIRA) ) is now available. On May 21, 2026, MIRA Pharmaceuticals amended its exclusive Ketamir-2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-expands-global-ketamir-2-license-for-clinical-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-expands-global-ketamir-2-license-for-clinical-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638507708","title":"Mira Pharmaceuticals Inc: Entered Into Amendment No 1 to Exclusive License Agreement With Miralogx Llc - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638507708","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638507708?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:08","pubTimestamp":1779883731,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN4240K6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638507050","title":"Mira Pharmaceuticals Inc - Expands Ketamir-2 Patent Portfolio to 10 Major Markets - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638507050","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638507050?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:08","pubTimestamp":1779883731,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nFWN4240K6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638507439","title":"Mira Pharmaceuticals expands Ketamir-2 license to worldwide rights across 10 major markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2638507439","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638507439?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:01","pubTimestamp":1779883291,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals expanded its exclusive Ketamir-2 license to worldwide rights under an amended agreement with MIRALOGX.Broader IP coverage spans 10 major markets, supporting global partnering options as Ketamir-2 advances toward Phase 2a in CIPN.The amendment leaves the previously disclosed core economic terms of the original license agreement largely unchanged.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL8dsWB5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638549778","title":"Mira Pharmaceuticals management to meet with Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2638549778","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638549778?lang=en_us&edition=fundamental","pubTime":"2026-05-27 00:54","pubTimestamp":1779814484,"startTime":"0","endTime":"0","summary":"Meeting to be held on May 27 hosted by Maxim. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-management-to-meet-with-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-management-to-meet-with-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635639740","title":"Mira Pharmaceuticals Q1 net loss narrows to $1.15 million; revenue flat at no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2635639740","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635639740?lang=en_us&edition=fundamental","pubTime":"2026-05-15 03:04","pubTimestamp":1778785473,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals posted a net loss of $1.15 million, narrowing from $1.78 million a year earlier, while loss per share improved to $0.03 from $0.11.Operating costs fell to $1.1 million from $1.81 million, as general and administrative expense dropped to $578,698 from $1.49 million.Research and development spending climbed to $524,781 from $314,404.Cash declined to $4.82 million from $6.35 million at Dec. 31, while short-term investments edged down to $4.59 million from $4.68 million.Ketamir-2 completed Phase 1 dosing and is being advanced toward a Phase 2a CIPN study in first half 2026, while MIRA-55 and SKNY-1 remained in preclinical development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL7wKZ09:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635759662","title":"MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635759662","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635759662?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:14","pubTimestamp":1778706865,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has issued an update. MIRA Pharmaceuticals, Inc. reported positive unblinded results from a completed Phase ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-reports-positive-phase-1-ketamir-2-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-reports-positive-phase-1-ketamir-2-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635275345","title":"Mira Pharmaceuticals publishes investor presentation on Ketamir-2 for chemotherapy-induced peripheral neuropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2635275345","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635275345?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:20","pubTimestamp":1778703609,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals highlighted Ketamir-2, an oral selective NMDA receptor modulator being developed for chemotherapy-induced peripheral neuropathy, a condition it estimates affects 30%-40% of chemotherapy patients with no FDA-approved treatments.Phase 1 program completed in 56 healthy volunteers with 0 serious adverse events, testing doses up to 600 mg.Phase 2a protocol submission targeted for H1 2026 under an active IND, with enrollment expected to begin in 2026 and first readout expected in Q1 2027.Planned Phase 2a design calls for a randomized, double-blind, placebo-controlled, three-period crossover study in 24 patients, evaluating 150 mg and 300 mg oral doses.Estimated all-in cost for Phase 2a cited at USD 4-6 million, with management describing the company as debt-free.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL4VqDyM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758990","title":"Mira Pharma reports positive Phase 1 results for Ketamir-2 oral NMDA modulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758990","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758990?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:04","pubTimestamp":1778702687,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals reported positive unblinded results from its completed Phase 1 trial of oral Ketamir-2; no future presentation was disclosed.Study met key early-stage objectives, with results supporting a favorable safety and tolerability profile in healthy volunteers.Data also indicated drug exposure consistent with potential once-daily dosing, subject to further clinical testing.Company is preparing to submit Phase 2a materials to FDA to start a mid-stage study in chemotherapy-induced peripheral neuropathy under its active IND.DEA review concluded Ketamir-2 is not classified as a controlled substance, removing a potential regulatory constraint ahead of later-stage development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDLbZfH5S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635943731","title":"Mira announces acceptance of peer-reviewed SKNY-1 manuscript","url":"https://stock-news.laohu8.com/highlight/detail?id=2635943731","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635943731?lang=en_us&edition=fundamental","pubTime":"2026-05-14 00:28","pubTimestamp":1778689697,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals (MIRA) announced the acceptance and publication of a peer-reviewed manuscript describing the preclinical pharmacology and acti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-announces-acceptance-of-peer-reviewed-skny-1-manuscript-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-announces-acceptance-of-peer-reviewed-skny-1-manuscript-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635843227","title":"MIRA highlights SKNY-1 preclinical data in new publication","url":"https://stock-news.laohu8.com/highlight/detail?id=2635843227","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635843227?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:00","pubTimestamp":1778673639,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) just unveiled an announcement. On May 13, 2026, MIRA Pharmaceuticals announced that a peer-reviewed manuscri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-highlights-skny-1-preclinical-data-in-new-publication?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-highlights-skny-1-preclinical-data-in-new-publication?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mirapharmaceuticals.com","stockEarnings":[{"period":"1week","weight":0.0042},{"period":"1month","weight":-0.0383},{"period":"3month","weight":-0.1482},{"period":"6month","weight":-0.3962},{"period":"1year","weight":-0.1811},{"period":"ytd","weight":-0.3682}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0162},{"period":"3month","weight":0.1169},{"period":"6month","weight":0.0626},{"period":"1year","weight":0.2223},{"period":"ytd","weight":0.0758}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.","exchange":"NASDAQ","name":"Mira Pharma","nameEN":"Mira Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mira Pharma(MIRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mira Pharma,MIRA,Mira Pharma股票,Mira Pharma股票老虎,Mira Pharma股票老虎国际,Mira Pharma行情,Mira Pharma股票行情,Mira Pharma股价,Mira Pharma股市,Mira Pharma股票价格,Mira Pharma股票交易,Mira Pharma股票购买,Mira Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mira Pharma(MIRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}